市場調查報告書

神經膠質母細胞瘤 (GBM) -流行病學預測 - 2030年

Glioblastoma Multiforme (GBM) - Epidemiology Forecast to 2030

出版商 DelveInsight Business Research LLP 商品編碼 955867
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
神經膠質母細胞瘤 (GBM) -流行病學預測 - 2030年 Glioblastoma Multiforme (GBM) - Epidemiology Forecast to 2030
出版日期: 2020年07月01日內容資訊: 英文 100 Pages
簡介

主要7個國家的神經膠質母細胞瘤 (GBM)的患病人數,2017年估計為28,259人。美國的2017年的患病人數是14,666人。歐洲5個國家中,2017年患病人數最多的是德國2,876人,其次是法國的2,683人,是西班牙最少的1,403人。日本2017年是1,899人。

本報告提供神經膠質母細胞瘤 (GBM) 的相關調查,關於其原因,徵兆與症狀,及病理學說明著,主要7個市場 (美國,德國,法國,義大利,西班牙,英國,日本) 的市場趨勢與預測。

目錄

第1章 主要考察

第2章 神經膠質母細胞瘤 (GBM)的概要

第3章 神經膠質母細胞瘤 (GBM)的摘要整理

第4章 疾病的背景和概要:神經膠質母細胞瘤 (GBM)

  • 簡介
  • 分類
  • 類型
    • 星細胞瘤
    • 室管膜瘤
    • 乏突起神經膠質瘤
    • 混合型神經膠質瘤
    • 視神經膠質瘤
  • 症狀
  • 病理學
    • GBM的肉眼及組織學性特徵
    • 遺傳及分子的病因
  • 神經膠質母細胞瘤的遺傳
    • 神經膠質母細胞瘤的遺傳性變異
  • 分子分類
    • 特定的分子生物標記
  • 神經膠質母細胞瘤的診斷
    • 神經學的檢驗
    • 血管造影術
    • 核磁共振影像(MRI)和電腦斷層攝影(CT)
    • 灌流MRI
    • MR光譜學
    • 組織學的診斷
    • 外科切片檢查
  • 彙整

第5章 流行病學和患者人口

  • 主要調查結果
  • 神經膠質母細胞瘤 (GBM)的主要7個市場的病例

第6章 神經膠質母細胞瘤 (GBM)的流行病學:各國

  • 美國
    • 假設和根據
    • 患病人數
    • 患病人數:性別
    • 患病人數:各類型
    • 患病人數:各年齡
    • 患病人數:各原發部位
    • 患病人數:腫瘤的各組織分類
  • 歐洲5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 附錄

  • 參考文件
  • 報告調查手法

第8章 DelveInsight的服務內容

第9章 免責聲明

第10章 關於DelveInsight

目錄
Product Code: DIEI0292

DelveInsight's 'Glioblastoma Multiforme (GBM) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Glioblastoma Multiforme (GBM) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Glioblastoma Multiforme (GBM) Understanding

Glioblastoma (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations. There is a remarkable development in GBM because it occurs via a complex network of various different molecular and genetic aberrations, which leads to significant changes in major signaling pathways. GBMs, as they extensively disperse throughout the parenchyma, making maximal surgical resection unattainable and having high level of vascularization, are lethal in nature.

GBM is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced process such as speech and emotions. While GBM is highly locally invasive (invading normal brain tissue), it rarely spreads to other organs beyond the brain. A highly aggressive, fast-growing cancer and treatment is often limited by the tumor location and the ability of a patient to tolerate surgery. Consequently, it is a particularly difficult cancer to treat.

Glioma is considered as the general term which is used to describe the primary brain tumors, and it is also classified to their presumed cell of origin accordingly. The classification includes astrocytic tumors (astrocytoma, anaplastic astrocytoma and glioblastoma), oligodendrogliomas, ependymomas, and mixed gliomas. Gliomas are classified into grade I TO IV on the basis of malignancy that is determined by the histopathalogical criteria. Although the location of GBM is commonly found in the supratentorial region (frontal, temporal, parietal, and occipital lobes), it is rarely located in the cerebellum part. Investigation of genetic and environmental factors of GBM have been done. Prior radiography, decreased susceptibility to allergy, immune factors and immune genes, as well as some nucleotide polymorphisms detected by genomic analysis are all included in the risk factors of the respective disease. The histological classification and tumor grading is a critical step for GBM diagnosis and prognosis.

GBM is a grade IV glioma according to the WHO 2007 classification and is the most common and lethal primary malignancy of the central nervous system. Despite multidisciplinary treatments such as surgery, chemotherapy, and radiotherapy, the median survival time for patients with GBM is only 14.6 months. Due to its high degree of invasiveness, radical tumor resection is not curative. From various experimental evidences it is explained that GBM contains a subpopulation of highly tumorigenic cells (GBM stem cells) from which recurrent GBM is thought to derive, and that GBM has the capacity to differentiate into multiple lineages of tumor genesis.

GBMs can be classified into primary and secondary GBMs:

  • Primary GBM occurs de novo without evidence of a less malignant precursor
  • Secondary GBM develops from initially low-grade diffuse astrocytoma (WHO grade II diffuse astrocytoma) or anaplastic astrocytoma (Grade III).

Glioblastoma Multiforme (GBM) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Gender-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Type-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Age-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Diagnosed Incident Population based on Primary Site Of Glioblastoma Multiforme (GBM) Tumour and Diagnosed Incident Population based on Histologic Classification of Glioblastoma Multiforme (GBM) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Glioblastoma Multiforme (GBM) Detailed Epidemiology Segmentation

  • The total diagnosed incident population of Glioblastoma Multiforme in the 7 major markets was estimated to be 28,259 in 2017. In case of Glioblastoma Multiforme patients in the United States, the diagnosed cases were 14,666 in 2017.
  • The total diagnosed incident cases of Glioblastoma Multiforme patients were found to be maximum in males as compared to females in the 7 MM during the study period of 2017-2030.
  • In the EU5 countries, the diagnosed incident population of Glioblastoma Multiforme was found to be maximum in Germany with 2,876 cases followed by France with 2,683 cases in 2017. While, Spain accounted for the lowest diagnosed incident population of 1,403 in 2017.
  • As per Delvelnsight's analysis, Japan had 1,899 diagnosed incident cases of Glioblastoma Multiforme in 2017.

Scope of the Report:

  • The report covers the descriptive overview of Glioblastoma Multiforme (GBM), explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Glioblastoma Multiforme (GBM).
  • The report provides the segmentation of the disease epidemiology for the 7MM by Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Gender-specific Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Age-specific Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Type-specific Diagnosed Incident Population of Glioblastoma Multiforme (GBM), etc.

Report Highlights:

  • Eleven Year Forecast of Glioblastoma Multiforme (GBM)
  • 7MM Coverage
  • Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM)
  • Delvelnsight has analysed type-specific data of GBM according to which there are two main types of Glioblasoma: Primary (de novo) and Secondary Glioblastoma, where the majority of cases (>90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion.
  • Diagnosed incidence according to histological classification of Glioblastoma Multiforme tumor was also assessed, which suggests that the conventional GBM type is more prevalent than giant cell GBM (GC-GBM), and gliosarcoma (GS).
  • In addition, gener-specific incidence of Glioblastoma Multiforme was also assessed. As per the analysis, GBm is more prevalent in males than in females.
  • The epidemiology segmentation also encompasses diagnosed incident population according to primary site of glioblastoma. As per DelveInsight estimates, it has been found that the primary site of GBM included maximum cases at parietal site, while minimum number of cases were found in unknown and other sites. This trend is clearly evident across all the 7MM countries for the study period 2017-2030.
  • The report also encompasses another major segment, i.e., Age-specific Diagnosed Incident Population of Glioblstoma Multiforme (GBM), wherein various age groups have been considered, such as <18, 18-34, 35-64, 65-74 and 75+. It has been found that GBM incidence increases with age peaking at 75-84 years and drops after 85 years.
  • Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of GBM. The market is expected to witness a significant positive shift owing to the positive outcomes of the several products during the developmental stage by key players such as Bayer, Diffusion Pharmaceuticals, VBL Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Oncoceutics, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics and Inovio Pharmaceuticals.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Glioblastoma Multiforme (GBM)?
  • What is the historical Glioblastoma Multiforme (GBM) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Glioblastoma Multiforme (GBM) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Glioblastoma Multiforme (GBM)?
  • Out of the above-mentioned countries, which country would have the highest incident population of Glioblastoma Multiforme (GBM) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to buy:

The Glioblastoma Multiforme (GBM) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Glioblastoma Multiforme (GBM) market.
  • Quantify patient share distribution in the 7MM for Glioblastoma Multiforme (GBM).
  • The Glioblastoma Multiforme (GBM) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Glioblastoma Multiforme (GBM) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1 Key Insights

2 Glioblastoma Multiforme Overview at a Glance

3 Executive Summary of Glioblastoma Multiforme (GBM)

4 Disease Background and Overview: Glioblastoma Multiforme (GBM)

  • 4.1 Introduction
  • 4.2 Classification of Glioblastoma Multiforme
  • 4.3 Glioblastoma Types
    • 4.3.1 Astrocytomas
    • 4.3.2 Ependymomas
    • 4.3.3 Oligodendrogliomas
    • 4.3.4 Mixed gliomas
    • 4.3.5 Optic pathway gliomas
  • 4.4 Symptoms
  • 4.5 Pathophysiology
    • 4.5.1 Macroscopic and Histological Features of GBM
    • 4.5.2 Genetic and Molecular Pathogenesis
  • 4.6 Inheritance of Glioblastoma Multiforme
    • 4.6.1 Genetic Variations of Glioblastoma Multiforme
  • 4.7 Molecular Classification
    • 4.7.1 Specific Molecular Biomarkers
  • 4.8 Diagnosis of Glioblastoma Multiforme
    • 4.8.1 Neurological Exams
    • 4.8.2 Angiograms
    • 4.8.3 Magnetic resonance imaging (MRI) and computerized Tomography (CT)
    • 4.8.4 Perfusion MRI
    • 4.8.5 MR spectroscopy
    • 4.8.6 Histological Diagnosis
    • 4.8.7 Surgical Biopsy
  • 4.9 Glioblastoma in Nut Shell

5 Epidemiology and Patient Population

  • 5.1 Key Findings
  • 5.2 7MM Total Diagnosed Incident Patient Population of Glioblastoma Multiforme

6 Country Wise-Epidemiology of Glioblastoma Multiforme

  • 6.1 United States
    • 6.1.1 Assumptions and Rationale
    • 6.1.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in the United States
    • 6.1.3 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
    • 6.1.4 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
    • 6.1.5 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
    • 6.1.6 Diagnosed Incident Population based on Primary Site of GBM in the United States
    • 6.1.7 Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United States
  • 6.2 EU5 Countries
    • 6.2.1 Assumptions and Rationale
  • 6.3 Germany
    • 6.3.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany
    • 6.3.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany
    • 6.3.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany
    • 6.3.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany
    • 6.3.5 Diagnosed Incident Population based on Primary Site of GBM in Germany
    • 6.3.6 Diagnosed Incident Population based on Histologic Classification of GBM in Germany
  • 6.4 France
    • 6.4.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in France
    • 6.4.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France
    • 6.4.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France
    • 6.4.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France
    • 6.4.5 Diagnosed Incident Population based on Primary Site of GBM in France
    • 6.4.6 Diagnosed Incident Population based on Histologic Classification of GBM in France
  • 6.5 Italy
    • 6.5.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy
    • 6.5.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy
    • 6.5.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy
    • 6.5.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy
    • 6.5.5 Diagnosed Incident Population based on Primary Site of GBM in Italy
    • 6.5.6 Diagnosed Incident Population based on Histologic Classification of GBM in Italy
  • 6.6 Spain
    • 6.6.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain
    • 6.6.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain
    • 6.6.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain
    • 6.6.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain
    • 6.6.5 Diagnosed Incident Population based on Primary Site of GBM in Spain
    • 6.6.6 Diagnosed Incident Population based on Histologic Classification of GBM in Spain
  • 6.7 United Kingdom
    • 6.7.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in the United Kingdom
    • 6.7.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom
    • 6.7.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom
    • 6.7.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom
    • 6.7.5 Diagnosed Incident Population based on Primary Site of GBM in the United Kingdom
    • 6.7.6 Diagnosed Incident Population based on Histologic Classification of GBM in the United Kingdom
  • 6.8 Japan
    • 6.8.1 Assumptions and Rationale
    • 6.8.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan
    • 6.8.3 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
    • 6.8.4 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
    • 6.8.5 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
    • 6.8.6 Diagnosed Incident Population based on Primary Site of GBM in Japan
    • 6.8.7 Diagnosed Incident Population based on Histologic Classification of GBM in Japan

7 Appendix

  • 7.1 Bibliography
  • 7.2 Report Methodology

8 DelveInsight Capabilities

9 Disclaimer

10 About DelveInsight

List of Tables

  • Table 1: Summary of Glioblastoma Multiforme, Market, Epidemiology and Key Events (2017-2030)
  • Table 2: Total Diagnosed Incident Patient Population of Glioblastoma Multiforme in the 7MM (2017-2030)
  • Table 3: Total Diagnosed Incident Population of Glioblastoma Multiforme in the United States (2017-2030)
  • Table 4: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017-2030)
  • Table 5: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017-2030)
  • Table 6: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017-2030)
  • Table 7: Diagnosed Incident Population based on Primary Site of GBM Tumor in the United States (2017-2030)
  • Table 8: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United States (2017-2030)
  • Table 9: Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany (2017-2030)
  • Table 10: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017-2030)
  • Table 11: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017-2030)
  • Table 12: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017-2030)
  • Table 13: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in Germany (2017-2030)
  • Table 14: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Germany (2017-2030)
  • Table 15: Total Diagnosed Incident Population of Glioblastoma Multiforme in France (2017-2030)
  • Table 16: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017-2030)
  • Table 17: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017-2030)
  • Table 18: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017-2030)
  • Table 19: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in France (2017-2030)
  • Table 20: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in France (2017-2030)
  • Table 21: Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy (2017-2030)
  • Table 22: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017-2030)
  • Table 23: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017-2030)
  • Table 24: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017-2030)
  • Table 25: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in Italy (2017-2030)
  • Table 26: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Italy (2017-2030)
  • Table 27: Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain (2017-2030)
  • Table 28: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017-2030)
  • Table 29: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017-2030)
  • Table 30: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017-2030)
  • Table 31: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in Spain (2017-2030)
  • Table 32: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Spain (2017-2030)
  • Table 33: Total Diagnosed Incident Population of Glioblastoma Multiforme in the United Kingdom (2017-2030)
  • Table 34: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom (2017-2030)
  • Table 35: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom (2017-2030)
  • Table 36: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom (2017-2030)
  • Table 37:Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in the UK (2017-2030)
  • Table 38: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United Kingdom (2017-2030)
  • Table 39: Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan (2017-2030)
  • Table 40: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017-2030)
  • Table 41: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017-2030)
  • Table 42: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017-2030)
  • Table 43: Diagnosed Incident Population based on Primary Site of GBM Tumor in Japan (2017-2030)
  • Table 44: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Japan (2017-2030)

List of Figures

  • Figure 1: Classification of Glioblastoma
  • Figure 2: Different types of Glioblastoma
  • Figure 3: Generalized transcription pathways related to Glioblastoma disease
  • Figure 4: Up-regulated Genetic Pathways in Glioblastoma
  • Figure 5: Overall pathways of IDH mutations
  • Figure 6: Chemistry of O6-Methylguanine-DNA Methyltransferase (MGMT)
  • Figure 7: Functioning of MicroRNA as a biomarker in Glioblastoma
  • Figure 8: Total Diagnosed Incident Patient Population of GBM in the 7MM (2017-2030)
  • Figure 9: Total Diagnosed Incident Population of Glioblastoma Multiforme in the US (2017-2030)
  • Figure 10: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2017-2030)
  • Figure 11: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2017-2030)
  • Figure 12: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2017-2030)
  • Figure 13: Diagnosed Incident Population based on Primary Site of GBM Tumor in the US (2017-2030)
  • Figure 14: Diagnosed Incidence based on Histologic Classification of GBM Tumor in the US (2017-2030)
  • Figure 15: Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany (2017-2030)
  • Figure 16: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017-2030)
  • Figure 17: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017-2030)
  • Figure 18: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017-2030)
  • Figure 19: Diagnosed Incident Population based on Primary Site of GBM Tumor in Germany (2017-2030)
  • Figure 20: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Germany (2017-2030)
  • Figure 21: Total Diagnosed Incident Population of Glioblastoma Multiforme in France (2017-2030)
  • Figure 22: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017-2030)
  • Figure 23: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017-2030)
  • Figure 24: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017-2030)
  • Figure 25: Diagnosed Incident Population based on Primary Site of GBM Tumor in France (2017-2030)
  • Figure 26: Diagnosed Incidence based on Histologic Classification of GBM Tumor in France (2017-2030)
  • Figure 27: Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy (2017-2030)
  • Figure 28: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017-2030)
  • Figure 29: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017-2030)
  • Figure 30: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017-2030)
  • Figure 31: Diagnosed Incident Population based on Primary Site of GBM Tumor in Italy (2017-2030)
  • Figure 32: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Italy (2017-2030)
  • Figure 33: Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain (2017-2030)
  • Figure 34: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017-2030)
  • Figure 35: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017-2030)
  • Figure 36: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017-2030)
  • Figure 37: Diagnosed Incident Population based on Primary Site of GBM Tumor in Spain (2017-2030)
  • Figure 38: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Spain (2017-2030)
  • Figure 39: Total Diagnosed Incident Population of Glioblastoma Multiforme in the UK (2017-2030)
  • Figure 40: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2017-2030)
  • Figure 41: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2017-2030)
  • Figure 42: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2017-2030)
  • Figure 43: Diagnosed Incident Population based on Primary Site of GBM Tumor in the UK (2017-2030)
  • Figure 44: Diagnosed Incidence based on Histologic Classification of GBM Tumor in the UK (2017-2030)
  • Figure 45: Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan (2017-2030)
  • Figure 46: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017-2030)
  • Figure 47: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017-2030)
  • Figure 48: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017-2030)
  • Figure 49: Diagnosed Incident Population based on Primary Site of GBM Tumor in Japan (2017-2030)
  • Figure 50: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Japan (2017-2030)